Bulletin
Investor Alert

Intellia Therapeutics Inc.

NAS: NTLA

GO
/marketstate/country/us

After Hours

/zigman2/quotes/207821052/composite

$

43.00

Change

-2.01 -4.47%

Volume

Volume 12,234

May 26, 2022, 6:24 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/207821052/composite

Previous close

$ 43.81

$ 45.01

Change

+1.20 +2.74%

Day low

Day high

$43.39

$46.20

Open
Open: 44.05

52 week low

52 week high

$38.85

$202.73

Open

Market cap

$3.32B

Average volume

1.04M

P/E ratio

N/A

Rev. per Employee

$78,062

EPS

-5.04

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/ntla

MarketWatch News on NTLA

  1. Intellia Therapeutics upgraded to outperform from perform at Oppenheimer

    8:28 a.m. Feb. 7, 2022

    - Tomi Kilgore

  2. Beam Gets FDA Nod for First Gene-Editing Trial

    9:10 a.m. Nov. 9, 2021

    - Barron's Online

  3. Prime Is the Newest Gene Editing, and It's Getting Better

    7:11 p.m. Oct. 20, 2021

    - Barron's Online

  4. This Fund Is Winning Big by Betting on Stocks That Help Humanity

    7:37 a.m. Sept. 27, 2021

    - Barron's Online

  5. Intellia Therapeutics started at buy with $173 stock price target at Stifel Nicolaus

    7:59 a.m. Sept. 24, 2021

    - Tomi Kilgore

  6. Intellia Therapeutics stock price target raised to $190 from $90 at Evercore ISI

    5:58 a.m. Aug. 6, 2021

    - Tomi Kilgore

  7. The Best and Worst Biopharma Stock Performers So Far in 2021

    11:32 a.m. June 30, 2021

    - Barron's Online

  8. Intellia Therapeutics price target raised to $168 from $106 at Raymond James, stock rated outperform

    7:37 a.m. June 29, 2021

    - Tonya Garcia

  9. Intellia Therapeutics price target doubled to $160 from $80 at Truist Securities, stock maintained at buy

    11:24 a.m. June 28, 2021

    - Tonya Garcia

  10. Intellia Stock Is Rocketing Because of a Gene-Editing Breakthrough

    9:21 a.m. June 30, 2021

    - Barron's Online

  11. First In-Vivo Gene Editing Data Look Good for Intellia

    8:40 a.m. June 28, 2021

    - Barron's Online

  12. Biotech M&A Has Been Slow This Year. Why It Might Get Busier.

    8:32 a.m. May 21, 2021

    - Barron's Online

  13. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/ntla

Other News on NTLA

  1. Graphite Bio: Selling For Much Less Than Net Cash

    12:14 p.m. May 25, 2022

    - Seeking Alpha

  2. The Correction In Biopharmaceutical Stocks Is Likely Over

    12:51 a.m. May 18, 2022

    - Seeking Alpha

  3. Why Editas Medicine's Shares Fell 28.9% This Week

    11:52 a.m. May 13, 2022

    - Motley Fool

  4. Intellia Therapeutics: Several Catalysts Expected For H2 2022

    5:59 p.m. May 12, 2022

    - Seeking Alpha

  5. Top 5 1st Quarter Trades of Atlas Venture Associates IX, LLC

    5:00 p.m. May 12, 2022

    - GuruFocus.com

  6. ARKG: Don't Expect Any Favorable Return In Short Or Medium Term

    10:06 a.m. May 11, 2022

    - Seeking Alpha

  7. 10-Q: INTELLIA THERAPEUTICS, INC.

    4:13 p.m. May 5, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  8. Intellia Therapeutics Q1 2022 Earnings Preview

    12:45 p.m. May 4, 2022

    - Seeking Alpha

  9. Notable earnings before Thursday's open

    11:07 a.m. May 4, 2022

    - Seeking Alpha

  10. Incyte (INCY) Lags Q1 Earnings and Revenue Estimates

    8:25 a.m. May 3, 2022

    - Zacks.com

  11. 3 Top Biotech Stocks Ready for a Bull Run

    7:40 a.m. April 20, 2022

    - Motley Fool

  12. Loading more headlines...
/news/pressrelease/company/us/ntla

Press Releases on NTLA

  1. Chau Khuong Joins Catalio Capital Management as General Partner

    3:00 p.m. May 25, 2022

    - BusinessWire - BZX

  2. Loading more headlines...

Rates »

Link to MarketWatch's Slice.